In the fight against pancreatic cancer, a combination of drugs outperformed other treatments in human cell and mouse models, and should be used in human clinical trials, UC San Diego researchers announced Wednesday.
Researchers at University of California San Diego School of Medicine have discovered a molecular pathway critical to the initiation of pancreatic tumors.
Tumor Initiation Driven by Stress-Resistant Cells in Pancreas miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
E-Mail
IMAGE: Andrew Lowy, MD, is the co-corresponding author of the study, professor of surgery at UC San Diego School of Medicine and chief of the Division of Surgical Oncology at Moores. view more
Credit: UC San Diego Health Sciences
Every 12 minutes, someone in the United States dies of pancreatic cancer, which is often diagnosed late, spreads rapidly and has a five-year survival rate at approximately 10 percent. Treatment may involve radiation, surgery and chemotherapy, though often the cancer becomes resistant to drugs.
Researchers at University of California San Diego School of Medicine and Moores Cancer Center, in collaboration with Sanford-Burnham-Prebys Medical Discovery Institute and Columbia University, demonstrated that a new tumor-penetrating therapy, tested in animal models, may enhance the effects of chemotherapy, reduce metastasis and increase survival.